Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 275 is a C2H2-type zinc finger protein encoded by the ZNF275 gene, located on chromosome Xq28[2][3][7]. It is part of the largest family of human transcription factors, characterized by zinc finger motifs that mediate DNA binding and regulate gene expression[1][5]. The specific biological function of ZNF275 remains largely uncharacterized, though it is conserved across eutherian mammals[3][7]. Recent evidence suggests an elevated role in cervical cancer, where increased ZNF275 expression promotes tumor proliferation and migration, potentially via the AKT/Bcl-2 signaling pathway[2]. Downregulation of ZNF275 inhibits tumor growth and can sensitize tumors to chemotherapy agents such as cisplatin when combined with AKT pathway inhibition[2]. No specific small-molecule drugs directly target ZNF275, but its expression levels may influence sensitivity to certain anti-cancer regimens. No well-documented non-oncology disease roles or safety liabilities are currently established for ZNF275.
Triciribine: AKT pathway inhibition in cells overexpressing ZNF275; Cisplatin: Chemotherapy, efficacy may be enhanced when ZNF275 is targeted
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 275 (ZNF275).